Financial statements Glenmark Pharmaceuticals
Balance sheet of Glenmark Pharmaceuticals
Company age:
Age:
17 y. 4 m.
Share capital:
Share capital:
50 000 PLN
Balance sheet data of GLENMARK PHARMACEUTICALS
|
Year
|
2018
|
2019
|
2020
|
2021
|
2023
|
|---|---|---|---|---|---|
| Total assets | 73 237 058,98 | 88 950 828,94 | 63 444 522,63 | 64 188 418,72 | 67 330 171,95 |
| A. Fixed assets | 7 833 504,28 | 2 097 640,46 | 2 279 795,53 | 5 168 820,94 | 4 687 347,88 |
| B. Current assets | 65 403 554,70 | 86 853 188,48 | 61 164 727,10 | 59 019 597,78 | 62 642 824,07 |
| C. Share capital contributions (basic funds) | - | - | - | - | - |
| D. Own shares (stocks) | - | - | - | - | - |
| Total liabilities | 73 237 058,98 | 88 950 828,94 | 63 444 522,63 | 64 188 418,72 | 67 330 171,95 |
| A. Equity | -1 842 556,08 | 874 600,51 | -983 631,24 | 3 560 090,33 | 5 698 622,51 |
| B. Liabilities and provisions for liabilities | 75 079 615,06 | 88 076 228,43 | 64 428 153,87 | 60 628 328,39 | 61 631 549,44 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 9 874 820,00 | 9 173 780,00 |
| II. Short-term liabilities | 61 157 602,34 | 72 681 875,80 | 54 941 334,99 | 36 160 498,73 | 36 062 786,95 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.